Planning a Health Canada PRCI Compliant Submission
How to set yourself up for a successful Health Canada PRCI submission
Certara2021年4月26日
Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Certara2021年4月21日
Part 2: Oligonucleotide therapeutic development: Pre-clinical and translational considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Certara2021年4月21日
Part 1: What are oligonucleotide therapeutics, and how do they work?
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Certara2021年4月21日
Plan to Accelerate Your Time to Drug Submissions
There are common themes driving how quickly you can get from your last database lock…
Certara2021年4月20日
A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development
Pediatric PBPK models have broad application in the drug development process and are being used…
Certara2021年4月20日
Overcome Research Hurdles: Expert Guidance for Complex Generic Drug Development
Do expensive bioequivalence studies stall your generic drug approval? Learn how you can streamline complex…
Certara2021年4月15日
Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States
Authors: Joseph McGuirk, Clint Divine, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Genovefa A. Papanicolaou…
Certara2021年4月8日
Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure
The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…
Certara2021年4月1日
Legislators: Bring all stakeholders to the table to lower drug costs
BY ROMAN CASCIANO, OPINION CONTRIBUTOR — 03/29/21 05:30 PM EDT No one is happy with the…
Certara2021年3月30日
